Zydus Lifesciences Ltd

Stage 2 · Advancing · week 19Setup 6.1 ★ FairStrong +7.2

As of 9 Oct 2026, Zydus Lifesciences is in Stage 2 — advancing, the uptrend phase, in week 19 (since 3 Jun 2026). It closed at ₹1,118, 8.0% below its 52-week high and above its 200-day average, which is rising. In Health Care, 44.6% of stocks are in Stage 2.

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. More about the company

₹1,117.5
+0.49% today
₹1.11L Cr · Large cap
Market Neutral — FadingHealth Care 44.6% in Stage 2-2.6 pts / 20dPharmaceuticals 51.3%-0.4 pts

Pro read

Pro

Our read

In Stage 2, but it has already run

Setup score

6.1 ★ Fair

Momentum

Steady

Edge

Strong +7.2

Setup-score rank among Stage 2 peers: #22 of 61 in Pharmaceuticals · #24 of 78 in Health Care

Is ZYDUSLIFE early, or has it already run? Pro answers that for every NSE stock, after every close.

₹2,999 · 12 months₹1,999 · 6 months
Loading price chart…
vs 52W High
-8.0%
₹860.6 lo₹1,215 hi
8.0% below 52W high — pullback range
How far this stock is from its 52-week high. A pullback of 3–20% while Stage 2 structure holds is typically a better entry than chasing near the high.
Stage Maturity
Week 19
1w13w26w
Week 19 — proven structure, sweet spot
How long this stock has been in Stage 2. The sweet spot is mid-run — enough time to prove the structure holds, not so long it's extended. Very fresh (wk 1–4) often needs more time to confirm.
vs 200 DMA
9.9%
200 DMA: ₹1,016.6 · rising
Long-term trend anchor. When stock and Nifty are both above their 200 DMA, the macro backdrop supports continuation.
Rel Volume
0.34x
vs 50-day avg
Low vol (0.5–1x) on pullbacks = resting, not being sold. High vol on breakouts = commitment. Volume spike on down days is a warning sign.
Trend Health
→
MA20 flat · +0.2% vs MA50 +0.6%
Two-layer momentum read: the glyph shows whether the 20-day MA is rising (↑/↗), flat (→), or rolling over (↓). The ⇈ flag fires when the 20-day MA is pulling away from the 50-day MA — short-term momentum building on top of the longer trend. Best when both glyphs agree.
1M
-2.4%
3M
-2.9%
6M
+25.3%
YTD
+20.4%
1Y
+12.7%
Sector
Health Care
↓ Peaking
Stage 2%
44.6%
20d Δ
-2.6pp
1M return
-4.9%
3M return
+0.2%
Sector Stage-2 % · last 20 days
This stock ranks #44 of 74 Stage 2 stocks in Health Care by RS.
Industry
Pharmaceuticals
→ Flat
Stage 2%
51.3%
20d Δ
-0.4pp
1M return
-4.2%
3M return
-0.6%
Industry Stage-2 % · last 20 days
Ranks #37 of 58 Stage 2 stocks in this industry.
Stage Cycle Timeline2023-07-14 → 2026-10-09
S2 14w
S2 42w
S4 28w
S2 18w
S4 16w
S2 18w
2023-07-142026-10-09
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 14w → S3 7w → S2 42w → S3 8w → S4 28w → S1 6w → S2 18w → S3 6w → S4 16w → S1 6w → S2 18w current
Total tracked: 169 weeks across 11 stage runs.
Scan Membership
Breakout Watch
Latest: 2026-06-03
2 appearances in last 60 days. First seen: 2025-07-18.
Stocks that stay in the scan for 13+ weeks are in the highest observed-return cohort — they keep qualifying because the structure remains intact, not by luck. Persistence in the scan is itself a quality signal.
Recent Stage Timeline
2026-10-09S2
Wk 19 · Vol 0.34x
2026-10-08S2
Wk 18 · Vol 1.12x
2026-10-07S2
Wk 18 · Vol 0.74x
2026-10-06S2
Wk 18 · Vol 1.03x
2026-10-05S2
Wk 18 · Vol 1.05x
2026-10-01S2
Wk 18 · Vol 1.70x
2026-09-30S2
Wk 17 · Vol 1.09x
2026-09-29S2
Wk 17 · Vol 1.63x
2026-09-28S2
Wk 17 · Vol 2.85x
2026-09-25S2
Wk 17 · Vol 1.45x
2026-09-24S2
Wk 17 · Vol 1.43x
2026-09-23S2
Wk 16 · Vol 0.79x
Sector Peers — Stage 2All →
BAFNAPH
wk 18 · 0.0% from hi
8.6
ZIMLAB
wk 22 · 0.0% from hi
8.3
KILITCH
wk 2 · -7.3% from hi
8.3
SMSPHARMA
wk 3 · -8.0% from hi
8.3
RPGLIFE
wk 16 · -12.0% from hi
7.6
Moving averages & range
50 DMA
₹1,143.9
200 DMA
₹1,016.6
52W High
₹1,215
52W Low
₹860.6
5D Low
₹1,112
Resistance levels (recent highs)
20d High
₹1,215
60d High
₹1,215
120d High
₹1,215
250d High
₹1,215
Next resistance
+8.7%
to 20d High
Ask the Market AI about ZYDUSLIFEAsk →
P/E (TTM)
21.7
Forward 23.3
Earnings Growth (YoY)
+8.7%
Revenue +16.2%
ROE
+18.3%
Profit margin +18.6%
Dividend Yield
0.09%
P/B 4.3
About this companyHealth Care· Pharmaceuticals

Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopaedic surgery, including pathologies affecting the hip and knee. The company was formerly known as Cadila Healthcare Limited and changed its name to Zydus Lifesciences Limited in February 2022. Zydus Lifesciences Limited was founded in 1952 and is headquartered in Ahmedabad, India. Zydus Lifesciences Limited is a subsidiary of Zydus Family Trust.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-09. Past data patterns are not indicative of future results. This page is a data analytics tool only.